Purchase Order 75F40122P00157
- Not listed
- This federal contract award from the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned for-profit manufacturer, is for the provision of human induced pluripotent stem derived cardiomyocytes. The $84,500.00 firm-fixed-price purchase order contract has a period of performance through March 20, 2017. The contract is not set aside for small businesses. Fujifilm Cellular Dynamics is a key supplier of specialized and proprietary human cell lines, including diverse...
- This is a firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell (iPSC)-derived human cell lines. The $79,500.00 contract is for the supply of human iPSC-derived cardiomyocytes (heart muscle cells) to support biomedical research, drug development, and toxicology screening initiatives. The...
- This contract award to Fujifilm Cellular Dynamics, Inc. (FCDI) is for the provision of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to the Food and Drug Administration (FDA). The $42,995 firm-fixed-price purchase order has a period of performance through December 31, 2024. FCDI is a foreign-owned, for-profit manufacturer of specialized human cell cultures, particularly those derived from induced pluripotent stem cells (iPSCs). The company has an extensive history of...
- This federal contract award, valued at $23,850.00, was issued by the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is designated as a Total Small Business set-aside and is for the delivery of CARDIOMYOCYTES, which are specialized cardiac muscle cells. Fujifilm Cellular Dynamics has a strong track record of supplying diverse...
- This is a firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The $11,940 contract is for the supply of cardiomyocytes (heart muscle cells) and does not have a small business set-aside designation. Fujifilm Cellular Dynamics has been a consistent provider of specialized cell products to various federal agencies,...
- The U.S. Food and Drug Administration (FDA) awarded a $98,725.00 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. (FCDI), a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is for the purchase of cardiomyocytes, which are heart muscle cells, and does not have a set-aside designation. FCDI is a key supplier of specialized cell products, particularly to the Department of Health and Human...
- This is a firm-fixed-price purchase order awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian agency within the Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a subsidiary of Fuji Photo Film Company LIMITED. The $18,195 contract is for the supply of induced pluripotent stem cell-derived human cardiomyocytes (iCell Cardiomyocytes). This specialized cellular product supports critical research initiatives, including drug development,...
- This firm-fixed-price purchase order was awarded by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The $79,500.00 contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research and drug development. This contract is not set aside for small...
- This is a $99,500.00 firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research, drug development, and toxicology screening. The contract has...
- This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of human induced pluripotent stem cell-derived cells. The $26,680 contract is to provide specialized cell cultures, including cardiomyocytes, neurons, astrocytes, and hepatocytes, to support the FDA's active research program. The award has no set-aside designation and is a sole-source award,...
The U.S. Food and Drug Administration awarded a $50,095 firm-fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. for the supply of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). The contract was awarded on June 3, 2022, with a completion date of June 2, 2023, and performance is based in Jefferson, Arkansas. Fujifilm Cellular Dynamics, a subsidiary of Japan-based Fuji Photo Film Company LIMITED, specializes in the production of biologically relevant human cells derived from induced pluripotent stem cells for biomedical research, drug development, and toxicology screening. This award carried no small business set-aside designation. The hiPSC-derived cardiomyocytes procured under this contract support the FDA's critical research and regulatory science initiatives, particularly in drug development and safety assessment. Fujifilm Cellular Dynamics has established itself as a key supplier of specialized cell products to multiple federal agencies within the Department of Health and Human Services, including the National Institutes of Health and National Center for Advancing Translational Sciences, delivering diverse cell types with high purity and reproducibility. The firm's federal contract portfolio reflects its competitive positioning based on proprietary technological capabilities in advanced cellular product development rather than small business classifications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $50.1k | 6/2/22 |